ZYNQUISTA sotagliflozin Updated Sep 1
Watch for Zynquista NDA resubmission announcement in Q4 2026, that event will signal whether Lexicon believes it has adequately addressed FDA concerns. Success would be a major de-risking event; failure or further delay would be a severe blow given the company's pipeline reliance on sotagliflozin. The ~41.6% implied upside to the analyst mean price target reflects the binary nature of this catalyst.
- First-in-class dual SGLT1/SGLT2 inhibitor with a unique mechanism that could offer advantages over selective SGLT2 inhibitors for type 1 diabetes with CKD
- Same molecule (sotagliflozin) is already FDA-approved as Inpefa for heart failure, demonstrating safety and regulatory familiarity
- Analyst consensus is bullish: 8 analysts with 3 Strong Buy and 5 Buy ratings; mean price target of $3.86 implies ~41.6% upside from ~$2.19
- FDA has rejected sotagliflozin for type 1 diabetes twice, once in 2019 and again with a CRL in December 2024, and an FDA advisory committee voted 11-3 against it, indicating significant regulatory hurdles
- An FDA advisory committee voted 11-3 against Zynquista in 2024, suggesting serious safety/efficacy concerns remain even after additional data submission
- Elevated short volume ratio (many days >60% short volume) indicates bearish positioning from shorter-term traders